Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE The role of serum tumor markers (STMs) in the modern management of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung cancer remains poorly described. 31707279 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE However, patients lacking EGFR mutations are not sensitive to EGFR-TKI treatment and the emergence of secondary resistance poses new challenges for the targeted therapy of lung cancer. 31777985 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. 31782583 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE PET/CT images of lung cancer patients were obtained from public databases and used to establish two datasets, respectively to classify histological subtypes (156 adenocarcinomas and 32 squamous cell carcinomas) and EGFR mutation status (38 mutant and 100 wild-type samples). 31659591 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE Several growth related genes such as EGFR and VEGF as well as tumour suppressor genes such as p53 have been implicated in LC pathogenesis and progression. 31770191 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE We investigated whether A2B receptor is involved in EGFR translocation and DNA damage response (γH2AX/53BP1 focus formation) of lung cancer cells by means of immunofluorescence studies. 31678144 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE Besides being a predictive biomarker of response to immunotherapy in lung cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with treatment outcomes of lung adenocarcinoma (ADC) harbouring epidermal growth factor receptor (EGFR) mutations, as reported studies are inconclusive and seldom addressed the issues of response to treatment and resistance. 31760310 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE <b>Conclusions:</b> In conclusion, metformin may potentially enhance the therapeutic effect and increase survival in type 2 DM patients with lung cancer receiving EGFR-TKI therapy. 31409137 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE There are numerous biomarkers for the lung cancer such as EGFR, CEA, CYFRA 21-1, ENO1, NSE, CA 19-9, CA 125 and VEGF. 31514848 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. 31662533 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE In this study, we determined the effects of T0901317 and/or an EGFR-TKI on the lung cancer cell lines A549 and HCC827-8-1 in vitro and in vivo. 30724772 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. 31634655 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE This study aimed to investigate the role of SCD1 inhibition by EGFR inhibitor (Gefitinib)-based anti-tumor therapy of lung cancer both in vitro and in vivo. 31019378 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 AlteredExpression disease BEFREE In conclusion, the results of the present study suggested that miRNA‑128‑b may regulate the expression of EGFR in NSCLC cells, and that optimizing targeted therapy is conducive to the development of novel therapeutic strategies for the treatment of patients with lung cancer. 31638205 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication. 31550632 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE The natural histories of, and treatment options for, epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancers (NSCLCs) are distinctly different from those of lung cancer that lacks actionable mutations. 31346927 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE In the present study, EGFR‑targeted nanoparticles were constructed and co‑delivered cisplatin (CDDP) and doxorubicin (DOX) for lung cancer therapy. 31545462 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. 31561631 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cancer. 30017644 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Irrespective of transformation, patients with EGFR/TP53/RB1-mutant lung cancers had a shorter time to discontinuation than EGFR/TP53- and EGFR-mutant -only cancers (9.5 versus 12.3 versus 36.6 months, respectively, p = 2 × 10<sup>-9</sup>). 31228622 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. 31010639 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 GeneticVariation disease BEFREE Lung cancer is one of the most serious threats to human where 85% of lethal death caused by non-small cell lung cancer (NSCLC) induced by epidermal growth factor receptor (EGFR) mutation. 31745155 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE Collectively, our findings indicate DUOX1 deficiency in lung cancers promotes dysregulated EGFR signaling and enhanced GSTP1-mediated turnover of EGFR cysteine oxidation, which result in enhanced nuclear EGFR localization and tumorigenic properties. 30890751 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE The aim of this study was to investigate the combined effect of P38 αspecific siRNA and EGFR inhibitor on apoptosis and proliferation of A549 lung cancer cell line. 30827261 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.600 Biomarker disease BEFREE To determine the predictive and prognostic roles of three blood-based biomarkers: circulating tumour DNA (ctDNA), circulating tumour cells (CTC) and carcinoembryonic antigen (CEA), in patients with advanced epidermal growth factor receptor-mutated (EGFR+) lung cancer. 31319980 2019